IO-202,Venetoclax
Immune-Onc Therapeutics,Roche,Abbvie
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)']
immune-onc therapeutics presents io-202 phase 1 data in patients with relapsed or refractory aml and cmml at the eha annual meeting 2023 
Breaking news from Business Wire